Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that mycophenolate mofetil was effective in reducing signs and symptoms of active lichen planopilaris in 83% of patients who had failed multiple prior treatments.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

This case report describes an autoimmune hepatitis patient who achieved remission with mycophenolate mofetil and corticosteroids after intolerance to azathioprine-based therapy.

This study found that mycophenolate may stabilize β-catenin and counteract interferon-γ-induced catagen changes in human dermal papilla cells, which could promote hair growth.

This case report describes how a treatment with mycophenolate mofetil and prednisone may be effective in managing autoimmune subepidermal blistering dermatosis in dogs while allowing for steroid reduction.

This study found that mycophenolate mofetil is effective for both induction and maintenance therapy in children with severe lupus nephritis, significantly improving proteinuria and antibody levels, without renal flares during maintenance.

In this study, MMF plus prednisolone was found to induce remission in 81% of patients with proliferative lupus nephritis, with fewer adverse effects such as alopecia and amenorrhea compared to CYC plus prednisolone, despite similar overall remission rates.

In this case study, a woman with frontal fibrosing alopecia and associated hyperpigmentation showed significant improvement in skin pigmentation and itch after 9 months of treatment with mycophenolate mofetil, highlighting its therapeutic potential for lichen planus pigmentosus linked to this condition.

This study found that mycophenolate mofetil can enhance skin pigmentation in vitiligo models by activating the WNT signaling pathway and increasing melanin-related gene expression.

In this study, tacrolimus-based treatment was found to result in fewer overall side effects compared to cyclosporine among Yemeni kidney transplant patients, although tacrolimus was associated with a higher incidence of diabetes.

This study found that treatment with Shunyou dispersible tablet and prednisone improved clinical symptoms in patients with lupus nephritis, showing significant benefits over time along with a good safety profile.

Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.

This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.

This study found that mycophenolate mofetil was associated with higher response rates and lower rates of serious side effects, including a lower mortality rate, compared to cyclophosphamide in lupus nephritis treatment.

This guideline outlines the management of systemic lupus erythematosus in adults but reports no new clinical findings.

This extensive review discusses the clinical manifestations, potential associations, and treatment approaches for lichen planus, but reports no new clinical results, highlighting gaps in evidence for therapeutic strategies.

This review discusses evidence-based guidance for managing primary cicatricial alopecias but reports no new clinical results, highlighting significant gaps in knowledge and the need for more quality trials.

This review update suggests that mycophenolate mofetil may increase complete disease remission in proliferative lupus nephritis compared to intravenous cyclophosphamide, but with low certainty of evidence.

Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.

This article reviews current diagnostic and treatment approaches for discoid lupus erythematosus, emphasizing the importance of early treatment and photoprotection, but reports no new clinical findings.

This study found that azathioprine may improve relapses and disability in patients with neuromyelitis optica spectrum disorder but is associated with higher adverse events compared to mycophenolate mofetil.

In this report, a 23-year-old woman developed nephrotic syndrome and was diagnosed with lupus nephritis after receiving the first dose of the AstraZeneca COVID-19 vaccine, but causation is not established.

No treatment showed clear superiority for lichen planopilaris.

This review discusses neutrophil-associated and infiltrative scarring alopecias, as well as promising new treatments, but reports no new clinical results.

This review discusses therapies for skin lesions in lupus erythematosus and reports no new clinical results, focusing on defining and managing refractory disease.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This article discusses the efficacy and safety of mycophenolate mofetil and hydroxychloroquine for treating lichen planopilaris and reports no new clinical results.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

This case study reports that adding adalimumab to a 12-year-old VKH patient's treatment allowed for ocular inflammation remission, vision improvement, and corticosteroid tapering, suggesting escalation of immunosuppression may be critical in pediatric VKH cases.